DIVISLABNSEDivi's Laboratories Limited· PharmaceuticalsHighNegative
Announced Sat, 21 Mar · 16:11 IST

Divi's Laboratories Limited has informed the Exchange about Draft Order issued under Section 144C(1) of the Income Tax Act, 1961 for FY2022-23.

Regulatory & Legal View source PDF

DIVISLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.3%1-day move
₹6101.00
prior close
₹6036.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.5-0.3-0.3-1.3-1.4-0.9-2.3-3.2-4.4+2.1+4.5+11.3+10.7
Up moveDown movePending
AI summary

Divi's Laboratories has received a Draft Assessment Order from the Income Tax Authority for FY2022-23 (Assessment Year 2023-24) under Section 144C(1) of the Income Tax Act. The order proposes additions and disallowances of Rs. 570.51 crore to the company's returned income, arising from Transfer Pricing adjustments on specified domestic transactions and certain corporate tax adjustments. The company has stated that penalty proceedings under Section 270A may be initiated separately for alleged under-reporting of income. Divi's Labs is evaluating the order and intends to file an appeal before the appropriate authority within the stipulated time. The matter relates to routine income tax assessment, not a SEBI or stock exchange regulatory action.

Likely market impact

The proposed Rs. 570.51 crore addition, if upheld after appeal, would result in a significant additional tax liability for the company. However, since this is only a draft order and the company plans to contest it, the near-term impact is likely limited to overhang and sentiment, with the final outcome depending on the appeal process.